At a glance
ClinicalIndex Comparison RecordN/ACompleted· 708 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Observational Program Evaluation of the Efficacy and Tolerability of Detralex Treatment in Patients With Chronic Venous Edema (CEAP Class С3) in Real Clinical Practice
In Brief
An observational study for Chronic Venous Disease. Completed, enrolled 708 participants across 1 site.
Detailed Summary
The VAP-PRO-C3 is a multicenter observational program, which is carried out in the frame of routine consultations and follow-up of patients. The program includes patients with chronic venous diseases (CVDs) of CEAP class C3. It is scheduled in Russia for 2018-2019. The program is expected to enroll 90 phlebologists from 60 cities of Russia. The planned number of patients is 900
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Venous Disease
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionJun 2019
Study CompletionJun 2019
TodayJul 2026
First PostedOct 29, 2018
Enrollment StartDec 6, 2018
Primary CompletionJun 15, 2019
Study CompletionJun 20, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.7 years ago